Could biologic drugs offer a better way to treat lupus kidney disease?
NCT ID NCT07340463
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether biologic drugs (belimumab or telitacicept) can improve kidney outcomes in people with active lupus nephritis better than standard therapy. About 50 participants will be randomly assigned to one of three treatment groups for six months. The goal is to see if these targeted drugs can help more patients achieve complete kidney remission with fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Belimumab or Telitacicept (biologic drugs) plus glucocorticoids, with or without mycophenolate mofetil
What this could lead to
If successful, this could point toward a more targeted, potentially safer treatment option for lupus nephritis that reduces reliance on standard immunosuppressants.
What could go wrong
This is a small, early-phase exploratory trial with only 50 participants, so results may not apply broadly. Biologics can cause serious infections or allergic reactions, and the study does not yet prove long-term safety or effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Research Ethics Committee of the General Hospital of Eastern Theater Command of the People's Liberation Army
RECRUITINGNanjing, Jiangsu, 210016, China
Contact Phone: •••-•••-•••• Email: •••••@•••••